CN102631482A - Chinese medicinal composition for preventing and treating diabetes and complications - Google Patents
Chinese medicinal composition for preventing and treating diabetes and complications Download PDFInfo
- Publication number
- CN102631482A CN102631482A CN2012101466601A CN201210146660A CN102631482A CN 102631482 A CN102631482 A CN 102631482A CN 2012101466601 A CN2012101466601 A CN 2012101466601A CN 201210146660 A CN201210146660 A CN 201210146660A CN 102631482 A CN102631482 A CN 102631482A
- Authority
- CN
- China
- Prior art keywords
- extract
- diabetes
- folium mori
- vitis viniferae
- fructus arctii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 48
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 88
- 239000003814 drug Substances 0.000 claims abstract description 36
- 201000010099 disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 239000000843 powder Substances 0.000 claims abstract description 9
- 239000008187 granular material Substances 0.000 claims abstract description 4
- 239000007902 hard capsule Substances 0.000 claims abstract 2
- 239000006187 pill Substances 0.000 claims abstract 2
- 239000007901 soft capsule Substances 0.000 claims abstract 2
- 239000003826 tablet Substances 0.000 claims abstract 2
- 210000004369 blood Anatomy 0.000 claims description 57
- 239000008280 blood Substances 0.000 claims description 57
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 40
- 235000009392 Vitis Nutrition 0.000 claims description 37
- 241000219095 Vitis Species 0.000 claims description 37
- 210000000582 semen Anatomy 0.000 claims description 35
- 238000001035 drying Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 10
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 54
- 238000002360 preparation method Methods 0.000 abstract description 16
- 230000036541 health Effects 0.000 abstract description 6
- 244000269722 Thea sinensis Species 0.000 abstract description 4
- 240000005373 Panax quinquefolius Species 0.000 abstract description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 abstract description 3
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 2
- 244000146462 Centella asiatica Species 0.000 abstract description 2
- 235000004032 Centella asiatica Nutrition 0.000 abstract description 2
- 240000000249 Morus alba Species 0.000 abstract description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 abstract description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 abstract description 2
- 240000006365 Vitis vinifera Species 0.000 abstract description 2
- 235000014787 Vitis vinifera Nutrition 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 62
- 102000004877 Insulin Human genes 0.000 description 31
- 108090001061 Insulin Proteins 0.000 description 31
- 229940125396 insulin Drugs 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 229960001031 glucose Drugs 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 201000001421 hyperglycemia Diseases 0.000 description 22
- 230000006870 function Effects 0.000 description 12
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 10
- 230000035922 thirst Effects 0.000 description 10
- 230000002218 hypoglycaemic effect Effects 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 6
- 229930182837 (R)-adrenaline Natural products 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229960005139 epinephrine Drugs 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 description 6
- 229920002414 procyanidin Polymers 0.000 description 6
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 5
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 5
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 5
- 230000023852 carbohydrate metabolic process Effects 0.000 description 5
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229960001052 streptozocin Drugs 0.000 description 5
- LXBIFEVIBLOUGU-JGWLITMVSA-N 1-Deoxynojirimycin Natural products OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000033679 diabetic kidney disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 102000016912 Aldehyde Reductase Human genes 0.000 description 3
- 108010053754 Aldehyde reductase Proteins 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- YZNNBIPIQWYLDM-HSUXUTPPSA-N Fagomine Chemical compound OC[C@H]1NCC[C@@H](O)[C@@H]1O YZNNBIPIQWYLDM-HSUXUTPPSA-N 0.000 description 3
- YZNNBIPIQWYLDM-ZLUOBGJFSA-N Fagomine Natural products OC[C@@H]1NCC[C@H](O)[C@H]1O YZNNBIPIQWYLDM-ZLUOBGJFSA-N 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- YZNNBIPIQWYLDM-UHFFFAOYSA-N L-fagomine Natural products OCC1NCCC(O)C1O YZNNBIPIQWYLDM-UHFFFAOYSA-N 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 239000010977 jade Substances 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002516 radical scavenger Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 2
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010007749 Cataract diabetic Diseases 0.000 description 2
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 108010001394 Disaccharidases Proteins 0.000 description 2
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 2
- 241000201295 Euphrasia Species 0.000 description 2
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 2
- 101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 2
- JXSVIVRDWWRQRT-UYDOISQJSA-N asiatic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C JXSVIVRDWWRQRT-UYDOISQJSA-N 0.000 description 2
- LBGFKBYMNRAMFC-PYSQTNCISA-N asiatic acid Natural products C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]5CC[C@@]34C)[C@]2(C)[C@H]1C)C(=O)O LBGFKBYMNRAMFC-PYSQTNCISA-N 0.000 description 2
- 229940011658 asiatic acid Drugs 0.000 description 2
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229960000673 dextrose monohydrate Drugs 0.000 description 2
- 201000007025 diabetic cataract Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- CLXOLTFMHAXJST-UHFFFAOYSA-N esculentic acid Natural products C12CC=C3C4CC(C)(C(O)=O)CCC4(C(O)=O)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(CO)C CLXOLTFMHAXJST-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- PRAUVHZJPXOEIF-AOLYGAPISA-N madecassic acid Chemical compound C1[C@@H](O)[C@H](O)[C@@](C)(CO)[C@@H]2[C@H](O)C[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C PRAUVHZJPXOEIF-AOLYGAPISA-N 0.000 description 2
- BUWCHLVSSFQLPN-UHFFFAOYSA-N madecassic acid Natural products CC1CCC2(CCC3(C)C(=CCC4C5(C)CC(O)C(O)C(C)(C5CCC34C)C(=O)O)C2C1C)C(=O)OC6OC(COC7OC(CO)C(OC8OC(C)C(O)C(O)C8O)C(O)C7O)C(O)C(O)C6O BUWCHLVSSFQLPN-UHFFFAOYSA-N 0.000 description 2
- 229940011656 madecassic acid Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 208000022530 polyphagia Diseases 0.000 description 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- NKYAAYKKNSYIIW-XVFCMESISA-N 5-aminoimidazole ribonucleoside Chemical compound NC1=CN=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NKYAAYKKNSYIIW-XVFCMESISA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- RFAWQHFQFXXRQB-UHFFFAOYSA-N Arctigenin 4'-gentiobioside Natural products CC1OC(OC2C(O)C(O)C(CO)OC2OC3C(O)C(O)C(OC4CCC5(C)C(CCC6(C)C5CC=C7C8CC(C)(C)CC(O)C8(C)CCC67C)C4(C)CO)OC3C(=O)O)C(O)C(O)C1O RFAWQHFQFXXRQB-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000003712 Complement factor B Human genes 0.000 description 1
- 108090000056 Complement factor B Proteins 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100036721 Insulin receptor Human genes 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 239000009022 Jinqi Substances 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- FEQSYBHDHIPRKS-UHFFFAOYSA-N N5-Ac-(??)-N5-Hydroxyornithine Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(CO)O4)O)O3)O)=CC=2)C(=O)OC1 FEQSYBHDHIPRKS-UHFFFAOYSA-N 0.000 description 1
- ATKYNAZQGVYHIB-IXXDHKBRSA-N Norhyoscyamine Natural products C1([C@@H](C(=O)OC2C[C@H]3CC[C@H](N3)C2)CO)=CC=CC=C1 ATKYNAZQGVYHIB-IXXDHKBRSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- ATKYNAZQGVYHIB-IZGVIRRGSA-N [(1r,5s)-8-azabicyclo[3.2.1]octan-3-yl] (2s)-3-hydroxy-2-phenylpropanoate Chemical compound C1([C@H](C(=O)OC2C[C@H]3CC[C@H](N3)C2)CO)=CC=CC=C1 ATKYNAZQGVYHIB-IZGVIRRGSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- -1 alkaloid 1-deoxynojirimycin disaccharides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- NODILNFGTFIURN-GZPRDHCNSA-N ginsenoside Rb2 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O NODILNFGTFIURN-GZPRDHCNSA-N 0.000 description 1
- PFSIGTQOILYIIU-UHFFFAOYSA-N ginsenoside Rb3 Natural products CC(=CCCC(C)(O)C1CCC2(C)C3CCC4C(C)(C)C(CCC4(C)C3CC(OC5OC(COC6OCC(O)C(O)C6O)C(O)C(O)C5O)C12C)OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C PFSIGTQOILYIIU-UHFFFAOYSA-N 0.000 description 1
- ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010023365 keratopathy Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- ATKYNAZQGVYHIB-UHFFFAOYSA-N tropaic acid nortropanyl ester Natural products C1C(N2)CCC2CC1OC(=O)C(CO)C1=CC=CC=C1 ATKYNAZQGVYHIB-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for preventing and treating related diseases such as diabetes and complications thereof. The Chinese medicinal composition comprises American ginseng or extract thereof, mulberry leaves or extract thereof, centella asiatica or extract thereof, great burdock achene or extract thereof, and grape seeds or extract thereof. Oral preparations such as hard capsules, soft capsules, tablets, granules, powder, pills, tea bags, medicinal liquor and oral liquid are prepared from the five combinations by utilizing the synergistic effects of each component. The composition can be applied to Chinese patent medicaments or health care products, and has the effect of preventing and treating the related diseases such as the diabetes and the complications thereof.
Description
Technical field
The invention belongs to medicine and field of food, is the compositions that a kind of natural product with relevant diseases such as diabetes of preventing and treating and complication thereof is processed.
Background technology
Diabetes are absolute or relative deficiency and the chronic endocrine metabolism property disease that causes by insulin, and its main feature is hyperglycemia and multiple complications and deposits.The sickness rate of China's diabetes demonstrates increases trend year by year, and wherein 90% is non-insulin-dependent diabetes mellitus.The patient adds up to 4,000 ten thousand, predicts China's diabetics in 2025 according to WHO and will break through 5,000 ten thousand.The diabetes characteristics are that chronic hyperglycemia is followed because of insulin secretion and effect the defective sugar, fat and the protein metabolism disorder that cause.Its secular hyperglycemia, hyperlipidemia are the major reasons that causes the body visceral organ injury, therefore, correct the important means that the glycolipid metabolism disorder is treatment diabetes and complication thereof.The infringement of rule of life, diet, environment, emotion and all kinds of chemical substances that it and people are daily all has confidential relation.Its basic pathology physiology is the absolute or relative hyposecretion of insulin in the body, thereby causes that carbohydrate, fat, protein, power and water separate the matter metabolism disorder.Diabetes (hyperglycemia) all can exert an influence to each age group, have become the public health problem in serious threat human health and life-span.
People think that diabetes are that insulin function goes down or insulin function is impaired and cause more, and hypoinsulinism in the diabetic patient causes blood sugar increasing.In fact, most type 2 diabetes mellitus patients' islet function does not have big infringement, and function is within normal range, and wherein 80% patient also has hyperinsulinemia.Therefore, be not insulin very little, but because insulin resistant, normal biological effect is not enough, cause blood glucose high, and too high blood glucose is only the direct inducement of many complication.The reason that produces insulin resistant mainly contains the excretory insulin molecule structure of B cell defectiveness, does not have normal physiological function, and Insulin receptor INSR is not enough, and in conjunction with reducing, histiocyte is to insulin insensitivity; The influence of insulin antibody and make insulin lose due function of blood sugar reduction; The hormonal readiness of antagonism insulin increases; To hypoglycemic activity of glucagon etc.; Therefore reduce or eliminate insulin resistant, make that normocrinic insulin plays one's part to the full in the body, just can reach the blood sugar lowering level and also fundamentally eliminate diabetes and complication.
At present, the oral drugs that are used for prevention and treatment diabetes (hyperglycemia) on the domestic and international market are a lot, and Chinese medicine is arranged, and Western medicine is also arranged.Western medicine mainly contains sulfonylurea such as glyburide, minidiab, biguanides such as metformin, metformin, glucosidase inhibitor such as acarbose etc.Chinese medicine mainly contains JIANGTANGSHU, JINQI JIANGTANG PIAN, YUQUAN WAN, the jade plate sheet etc. of quenching one's thirst.These medicines are removed on diabetes patient's misery and have been played great role in treatment and prevent diabetes.But along with the variation with disease that increases of diabetes patient's quantity, exploitation prevents safer and more effectively and the medicine or health product of treating diabetes (hyperglycemia) remain the significant work of ten minutes.
The present invention is exactly a kind of Chinese medicine composition with relevant diseases such as diabetes of preventing and treating and complication thereof of finding and extract from natural plants.Said composition is to become composition of natural products by the effective ingredient innovative combination, from several kinds of different effects mechanism treatment diabetes of starting with, reaches combination of long drives and drop shots, and the effect of treating both the principal and secondary aspects of a disease is in the hope of having significant breakthrough and raising from curative effect and safety.
Radix Panacis Quinquefolii is the root of Araliaceae Radix Panacis Quinquefolii Panax quinquefolium L..Also name Radix Panacis Quinquefolii " property of medicine is examined ", Radix Panacis Quinquefolii " middle traditional Chinese medicines are planted will " etc.Sweet in the mouth, little hardship, cool in nature.GUIXIN, lung, kidney channel.Function with lung benefiting the moon, clear asthenic fire, promoting the production of body fluid to quench thirst.Cure mainly deficiency of the lung chronic cough, lose blood, dry throat and mouth, deficiency-heat be tired tired.Radix Panacis Quinquefolii contains the ginseng polysaccharide of hypoglycemic activity, called after karusanA, B, C, D, E and water solublity crude pectin, hydrochloric acid soluble pectin, aminoacid, trace element and saponin.Results of study such as John Zeqi Luo show, Radix Panacis Quinquefolii has the effect that human glucose reaches dynamic equilibrium of regulating, and the sick cause of disease of most of glycosurias is because due to the function of pancreatic beta cell excreting insulin is destroyed.Preliminary study finds that Radix Panacis Quinquefolii extract can suppress the activity of the UCP-2 in the pancreatic beta cell mitochondrion, improves insulin synthesis capability and anti-apoptotic.So; Radix Panacis Quinquefolii extract can stimulate the generation of insulin, the loss of prevention β cell through the activity that suppresses mitochondrion UCP-2; The result causes the raising of ATP level; The increase of anti-apoptotic factor B cl-2, the short apoptosis factor caspase-9 of downward modulation simultaneously, thus reduce apoptotic generation.Find in the research to the effective ingredient Rb1 of Radix Panacis Quinquefolii, Rg such as HasegawaH; The ginsenoside has the function that promotes that glucose shifts under normal conditions; The ginsenoside Rb1 just can increase (24 ± 5%) under the concentration conditions of minimum 1mmol/L glucose shifts physiologically active, and the ginsenoside Rg3 also shows the important function that suppresses sheep red blood cell (SRBC) running glucose to inducing.People such as Yokozawa T discover that the ginsenoside Rb2 can activate the lipid metabolism and the carbohydrate metabolism of rat model.So explain, Radix Panacis Quinquefolii can blood sugar lowering, regulate insulin secretion, promote carbohydrate metabolism and lipid metabolism, and the treatment diabetes are had certain assosting effect.
Folium Mori are the dried leaves of moraceae plants Mulberry Morus alba L..Have dispelling wind and heat pathogens, clearing away lung-heat and moistening for dryness, the effect of liver heat removing and eyesight improving mainly contains flavone, polysaccharide and alkaloid.Compendium of Material Medica record Folium Mori are hands, the bright medicine of foot sun, control the consumptive fever cough, and the long hair that makes eye bright is only quenched one's thirst.Japan's ancient book " eating tea health preserving note " is also put down in writing Folium Mori has the effect that improves " drinking-water is sick ".Essentials of Matea Medica record Folium Mori are only quenched one's thirst for tea.Studying data at home and abroad confirms that alkaloid and polysaccharide are blood sugar reducing components main in the Folium Mori.The hypoglycemic activity of Folium Mori is realized through two approach: the one, and through alkaloid 1-deoxynojirimycin disaccharides catabolic enzyme activity is produced inhibitory action, thereby suppress the absorption of small intestinal disaccharidase, reduce the peak value (Kimura, 1995) of blood glucose after eating; The 2nd, promoting through Folium Mori alkaloid fagomine and polysaccharides of Folium Mori that the β cell divides must insulin, and insulin can promote cell to the utilization of sugar, hepatic glycogen is synthetic and improve carbohydrate metabolism, finally reaches hypoglycemic effect (Chen Fujun etc., 1996).Isolated polyhydroxy norhyoscyamine has very strong glycosidase inhibiting function (Asano etc., 1994) from Folium Mori; N-Me-DNJ, GAL-DNJ and fagomine be blood sugar lowering level significantly, wherein GAL-DNJ and fagomine hypoglycemic activity the strongest (Kimura etc., 1995).The rat diabetes that Folium Mori cause alloxan at ecdysterone; Or the mice hyperglycemia that epinephrine, glucagon, AIS cause all has hypoglycemic activity.Ecdysterone promotes that glucose changes glycogen into, but does not change intact animal's blood sugar level.Someone thinks that contained some aminoacid can stimulate secretion of insulin with blood sugar lowering in the Folium Mori.Simultaneously, Folium Mori are edible resource, do not have toxic and side effects, and the safety using amount of 1 lumbar injection of 10% Folium Mori injection mice is equivalent to 250 times of people's consumption.To be equivalent to 60 times of people's consumption, harmless to liver, kidney, lung etc. continuously to mouse peritoneal injection 21 days.
Herba Centellae is the herb of samphire Herba Centellae Centella asiatica Linn., and the beginning is stated from Shennong's Herbal, classifies middle article as, and is bitter, hot, cold, returns the liver,spleen,kidney warp, has clearing away heat-damp and promoting diuresis, the effect of removing toxic substances and promoting subsidence of swelling.Be used for jaundice due to damp-heat, heatstroke diarrhoea, sand Stranguria stranguria with blood, carbuncle sore tumefacting virus, traumatic injury.In recent years research report Herba Centellae has the promotion wound healing, softening cicatrix, and psoriasis, antidepressant, resisting hyperplasia of mammary glands, anti-hepatic fibrosis, anticancer, the treatment edema protects the liver the effects such as treatment of blood sugar lowering and complication.The effective ingredient of Herba Centellae is asiatic centella total saponins, asiatic acid, Madecassic acid etc.; Song Chun studies clearly and has reported that effective ingredient asiatic acid, the Madecassic acid in the Herba Centellae has the effect that reduces post-prandial glycemia and prevent and treat diabetes, and its principle is to produce effect through the activity that suppresses alpha-glucosidase; Zheng Chenghong discovers; The Herba Centellae aqueous extract has obvious blood sugar lowering level; Lose weight; Blood fat reducing and insulin resistance index level, improve the effect of type 2 diabetes mellitus rat insulin opposing, the effect of its blood sugar lowering, blood lipid level and metformin therapeutic equivalence, effect of its reduction IRI level is superior to metformin.Wang Xuesong discovers, Asiatic polysaccharide have protein phosphatase PTP1B inhibitor effect, and regulate the effect of immunity.
Fructus Arctii is the dry mature fruit of Compositae biennial herb plant Fructus Arctii Arctium lappa L..Cold in nature, acrid in the mouth, hardship.Dispelling wind and heat pathogens, lung qi dispersing rash, resolving toxin and disinhibiting the throat.Be used for anemopyretic cold, cough with copious phlegm, measles, rubella, laryngopharynx swelling and pain, mumps erysipelas, carbuncle sore tumefacting virus.Fructus Arctii contains Arctiin (arctiin), arctigenin-4'-gentiobioside A, B, fatty wet goods composition.Fructus Arctii has inhibitory action to staphylococcus aureus, Diplococcus pneumoniae.Extract can reduce rat blood sugar significantly enduringly.Chinese medicine institute of Shanghai Univ. of Traditional Chinese Medicine research confirms, Fructus Arctii treatment diabetic nephropathy (DN) mechanism and reduction urine protein, microdose urine protein and to influence nephridial tissue transforming growth factor p1 (TGF-p1) relevant with the expression of monokaryon chemotactic protein 1 (MCP-1) mRNA.Research worker is an animal model with the inductive diabetes rat of streptozotocin (STZ); The result shows; Fructus Arctii extract can obviously improve STZ rat polydipsia, polyphagia and become thin, and reduces urine protein, microdose urine protein, reduces the expression of TGF-p1mRNA, MCP-1mRNA.The renal damage that improves diabetes rat possibly expressed through alleviating MCP-1mRNA by Fructus Arctii extract.Fructus Arctii and extract thereof can effectively reduce the diabetes rat microdose urine protein, reach twenty-four-hour urine albumen, endogenous creatinine clearance rate.Fructus Arctii and extract thereof can reduce the blood sugar level of DN rat, reduce the excretion rate of urine protein, can filter through the height that alleviates the DN rat kidney, HT, thus renal function protecting.Bibliographical information Fructus Arctii extract has stronger aldose reductase inhibitory action, can be used for preparation control diabetic complication---like the medicine of diabetic cataract, retinopathy, keratopathy and diabetic peripheral neuropathy.
Semen Vitis viniferae is the leftover bits and pieces of grape wine factory, products therefrom behind separation Pericarpium Vitis viniferae, the stem of Fructus Vitis viniferae after drying.Semen Vitis viniferae contains rich in amino acid, vitamin, mineral and a large amount of procyanidins.Semen Vitis viniferae extract procyanidin (OPC) is a kind of free radical scavenger efficiently.The oxidative function of its free radical resisting is 50 times, ascorbic 20 times of vitamin E.Can remove deleterious free radical in the human body, the protection human cell tissue exempts to be prevented kind more than 80 and free radical diseases associated such as allergy, cancer, aging by the oxidative damage of free radical.Just be based on this effect of Semen Vitis viniferae, European people claims that Semen Vitis viniferae is cosmetics in the natural body, and it can recover the collagen protein vigor, makes skin level and smooth and flexible.Semen Vitis viniferae still is natural sunlight overcover, can stop ultraviolet infringement skin.Semen Vitis viniferae can reduce low density cholesterol in the blood, can improve the high density level of cholesterol simultaneously, and both take into account, thus angiocardiopathy preventing.In addition, Semen Vitis viniferae extract contains abundant vitamin E, and vitamin E is famous antioxidant, so the effect of Semen Vitis viniferae also comprises the prevention various diseases, makes skin and the muscle state of keeping fit simultaneously.Semen Vitis viniferae also has anti-prostate tumor and anti-liver neoplasm effect.Thereby protection human organ and tissue are prevented and treated more than 100 kind of heart disease, cancer, senilism, diabetes, arteriosclerosis etc. by the free-radical induced disease.
In sum, five kinds of Chinese medicine share with different effective substances all has very clear and definite blood sugar lowering pharmacology effect from different action target spots and approach, can be with diabetes patient's blood glucose regulation to normal level.Therefore said composition can be used for preparing medicine and the health product with relevant diseases such as diabetes of preventing and treating and complication thereof.
Summary of the invention
The inventor rest on a scientific basis theory, through repetition test, selected the Ministry of Public Health regulation for use be food be again that medicine carries out prescription with the medicine that can be used for health food, so should form as safe as a house, without any side effects by prescription.Chosen the health food that the Radix Panacis Quinquefolii that can directly take, Folium Mori, Fructus Arctii, Herba Centellae, five kinds of raw materials of Semen Vitis viniferae have treatment diabetes and complication thereof in order to preparation the present invention.When each raw material of choosing health food of the present invention carries out combination collocation, must consider effect that they can be brought into play separately and the trade-off effect that they are arranged in pairs or groups and can produce.At first, selecting Radix Panacis Quinquefolii, is because Radix Panacis Quinquefolii is through changing the metabolism of cell; Increase secretion of insulin; The apoptosis that reduces cell comes beta Cell of islet is worked, and promotes carbohydrate metabolism and lipid metabolism, blood fat reducing simultaneously and platelet aggregation rate; Can obviously improve diabetic symptom, like weak, xerostomia etc.Theory of Chinese medical science is also thought Radix Panacis Quinquefolii sweet in the mouth, little hardship, and is cold in nature, and it is extensive to be suitable for the crowd.Has supplementing QI and nourishing YIN, promoting the production of body fluid to quench thirst, allaying tiredness, the Fructus Alpiniae Oxyphyllae of calming the nerves, of the effect of cool heart spleen to fall asthenic fire and to relieve summer heat.Selecting Folium Mori, is because Folium Mori have blood fat reducing, suppresses the effect of the generation of deleterious peroxide; Contain 1-deoxynojirimycin (DNJ) in the Folium Mori; DNJ is as the inhibitor of alpha-glucosidase, thereby the inhibition small intestinal reduces the peak value of food back blood glucose to the absorption of disaccharidase; Polysaccharides of Folium Mori promotes β emiocytosis insulin, and insulin can promote cell to the utilization of sugar, hepatic glycogen is synthetic and improve carbohydrate metabolism, finally reaches hypoglycemic effect.Theory of Chinese medical science is thought Folium Mori bitter but sweet flavor, cold, goes into the lung Liver Channel, light clear the evacuation, and sweet cold is moistened, but clearing away lung-heat, lung moistening is dry, to alleviate deficiency of both vital energy and Yin, production of dryness-heat in the interior, the main symptom of thirst and drinking; Compendium of Material Medica record Folium Mori have the long hair of making eye bright, and only quench one's thirst, and essentials of Matea Medica record Folium Mori are only quenched one's thirst for tea.Select for use we to be based on the combination of modern study and traditional Chinese medical science ancient books medical science record science for main composition on Folium Mori.Selecting Fructus Arctii to add this prescription, is because Fructus Arctii has blood sugar lowering, reduces the excretion rate of urine protein, can be through alleviating height filtration, the HT of kidney, thus renal function protecting.Simultaneously, Fructus Arctii has stronger aldose reductase inhibitory action, can be used to treat diabetic complication---like diabetic cataract, retinopathy, keratopathy and diabetic peripheral neuropathy etc.The traditional Chinese medical science thinks that Fructus Arctii is arduous and tremble with fear, to Qiu Naicheng, must the refrigerant gas in the world, and have lung heat clearing and rush down the stomach effect.Select Herba Centellae to add we; Be because Herba Centellae has the activity that suppresses alpha-glucosidase; Has obvious blood sugar lowering level; Lose weight, blood fat reducing and insulin resistance index level, improve the effect of type 2 diabetes mellitus rat insulin opposing, simultaneously Asiatic polysaccharide have protein phosphatase PTP1B inhibitor effect, and regulate the effect of immunity.The traditional Chinese medical science is thought, Herba Centellae is bitter, hot, cold, returns the liver,spleen,kidney warp, has clearing away heat-damp and promoting diuresis, the effect of removing toxic substances and promoting subsidence of swelling.Select Semen Vitis viniferae to add this prescription; Be because applicant's process test of many times; Confirmed that rising has certain resistance inhibitor action, scalable blood fat, blood fat reducing level to the procyanidin in the Semen Vitis viniferae to blood fat; Reduce the content of liver cholesterol, triglyceride, and procyanidin also has the effect of auxiliary scavenger interior free yl.But because procyanidin scavenger interior free yl effect; Be equipped with again and have the Folium Mori that can suppress harmful peroxide nucleus formation in the body and unite use; Can bring into play coordinative role; Further strengthen the ability of directly or indirectly removing interior free yl, reach the effect that harmful material in the body is removed by comprehensive system; And Fructus Arctii, Herba Centellae, Folium Mori, procyanidin all can improve blood glucose metabolism, blood fat reducing.Radix Panacis Quinquefolii and Folium Mori also can promote insulin secretion, so their comprehensive uses can be played the effect of good auxiliary hyperglycemic to human body.So all article share, can mutually promote, mutual synergism, reach real hypoglycemic purpose.
So; One of the object of the invention is; Based on modern pathology molecular mechanism and the bonded principle of Traditional Chinese medical theory; Through a large amount of discovering, the mixture of Radix Panacis Quinquefolii or extract, Folium Mori or extract, Herba Centellae or extract, Fructus Arctii or extract, Semen Vitis viniferae or extract has significant curative effect for treatment of diabetes, can be used for being prepared into the medicine of treatment diabetes.This modern composition of natural products; Wherein contain a large amount of Protein-tyrosine-phosphatases (PTP1B) inhibitor composition, aldose reductase inhibition composition, alpha-glucosidase inhibitor composition, promoted insulin secretion composition, component for reducing blood fat, elimination oxygen-derived free radicals composition; Synergism, many target spots, multipath effect each other; Diabetes patient's body is fundamentally regulated in the combination of five medicines comprehensively, improves diabetes patient's physical condition, and; The contained different effective substances of Chinese medicine of the five flavours all have very clear and definite blood sugar lowering pharmacology effect from different action target spots and approach, can be with diabetes patient's blood glucose regulation to normal level.Can be used for preparing medicine and health product with relevant diseases such as diabetes of preventing and treating and complication thereof.Have tangible novelty and technological progress.
Two of the object of the invention is; Each Chinese medicine synergism in this prescription has reduced insulin resistant, has improved the sensitivity of insulin; Make it give play to original biological effect; Thereby reach the therapeutical effect of blood sugar lowering and diabetic complication, the effect that this natural compositions reaches is that present existing chemical drugs and Chinese medicine preparation treatment diabetes are not available, and this is the most outstanding contribution of the present invention.
Technical problem to be solved by this invention is from natural plants Radix Panacis Quinquefolii, Folium Mori, Herba Centellae, Fructus Arctii, Semen Vitis viniferae, to extract active component, the preparation composition of natural products with blood sugar reducing function.
The invention provides the compositions that a kind of Chinese medicine with relevant diseases such as diabetes of preventing and treating and complication thereof is processed, said composition comprises Radix Panacis Quinquefolii 50-100 part, Folium Mori 200-500 part, Herba Centellae 100-300 part, Fructus Arctii 100-300 part, Semen Vitis viniferae 50-200 part.Also can be Radix Panacis Quinquefolii extract 10-30 part, Folium Mori extract 40-100 part, Herba Centellae extract 20-50 part, the 20-50 of Fructus Arctii extract part, Semen Vitis viniferae extract 10-30 part.Process according to aforementioned proportion mixing composition active ingredient and pharmaceutic adjuvant.
Another object of the present invention has provided the method for from Radix Panacis Quinquefolii, Folium Mori, Herba Centellae, Fructus Arctii, Semen Vitis viniferae, extracting active component respectively, and this method comprises:
(1) Folium Mori extract preparation: Folium Mori extract 1-3 time with 8-20 times of deionized water, and each 1-3 hour, to filter, filtrating concentrates, and drying is pulverized, and promptly gets Folium Mori extract;
(2) Herba Centellae extract preparation: Herba Centellae is extracted 2-4 time with 8-20 times of deionized water, and each 1-3 hour, to filter, filtrating concentrates, and drying is pulverized, and promptly gets Herba Centellae extract;
(3) Fructus Arctii extract's preparation: Fructus Arctii extracts 2-3 time with the alcoholic solution of 8-14 times of 40%-90%, and each 1-3 hour, filter, filtrate recycling ethanol concentrates, and drying is pulverized, and promptly gets Fructus Arctii extract;
(4) Semen Vitis viniferae extract preparation: Semen Vitis viniferae extracts 2-3 time with the alcoholic solution of 8-14 times of 30%-80%, and each 1-3 hour, filter, filtrate recycling ethanol concentrates, and is drying to obtain Semen Vitis viniferae extract;
(5) Radix Panacis Quinquefolii powder is broken into fine powder.
Another object of the present invention provided above-mentioned from Radix Panacis Quinquefolii, Folium Mori, Herba Centellae, Fructus Arctii, Semen Vitis viniferae isolating active component prevent and treat the medicine of diabetes and the application in the health food in preparation.
The present invention with respect to prior art have determined curative effect, have no side effect, taking convenience, cheap advantage.
Because the present invention discloses the effect that the compositions of being made up of Radix Panacis Quinquefolii or extract, Folium Mori or extract, Herba Centellae or extract, Fructus Arctii or extract, Semen Vitis viniferae or extract has relevant diseases such as diabetes of preventing and treating and complication thereof first; Therefore; This compositions cooperated separately or with other active constituent or adjuvant process medicament; So long as this medicament is used for prevention and treatment hyperglycemia and complication thereof, all belong to protection scope of the present invention.Compositions of the present invention all has the effect of prevention and treatment hyperglycemia when processing any dosage form.
By Radix Panacis Quinquefolii or extract, the compositions (abbreviation compositions) that Folium Mori or extract, Herba Centellae or extract, Fructus Arctii or extract, Semen Vitis viniferae or extract are formed has hypoglycemic activity, is confirmed through following pharmacodynamic experiment.
1, these article compositions causes the influence of mice hyperglycemia to glucose
Get 60 of male and female half and half mices, be divided into 6 groups at random, be respectively blank group (10ml/kg water) by body weight; Model control group (10ml/kg water), jade plate are quenched one's thirst sheet group, compositions group according to the following table administration, in 7 days every day gastric infusion once; Irritate the long-pending 10ml/kg that is of body of stomach, fasting is 5 hours before the last administration, and the last administration is after 2 hours; Except that the blank group, all the other respectively organized equal lumbar injection glucose 2g/kg, respectively at behind the injectable dextrose monohydrate 0.5,1 and 2 hour; With sacrifice of animal, get blood, survey blood glucose with glucose oxidase method.Result of the test is seen table 1.
These article of table 1 compositions causes the influence of mice hyperglycemia to glucose
Compare with model control group: * P < 0.05; * P < 0.01; * * P < 0.001
The result shows: these article can obviously reduce the hyperglycemia that glucose causes in 0.5 and 1 hour behind injectable dextrose monohydrate, and tangible dose-effect relationship is arranged, and in the time of 2 hours, did not have obviously to reduce the mice hyperglycemia that glucose causes.
2, these article cause the influence of mice hyperglycemia to epinephrine
Get 60 of male and female half and half mices, be divided into 6 groups at random, be respectively blank group (10ml/kg water) by body weight; Model control group (10ml/kg water), jade plate are quenched one's thirst sheet group, compositions group according to the following table administration, in 7 days every day gastric infusion once; Irritate the long-pending 10ml/kg that is of body of stomach, fasting is 5 hours before the last administration, and the last administration is after 2 hours; Except that the blank group, all the other respectively organize equal lumbar injection epinephrine 240ug/kg, respectively at the injection epinephrine after 0.5,1 and 2 hour; With sacrifice of animal, get blood, survey blood glucose with glucose oxidase method.Result of the test is seen table 2.
These article of table 2 compositions causes the influence of mice hyperglycemia to epinephrine
Compare with model control group: * P < 0.05; * P < 0.01; * * P < 0.01
The result shows: these article compositions all can obviously reduce the hyperglycemia that epinephrine causes in observed time range, and is the most remarkable with effect in 0.5,1 hour especially.Effect was relatively poor relatively in 2 hours, but certain effect is also arranged.
3, these article compositions causes the influence of mice hyperglycemia to streptozotocin
80 of male mices are got 10 at random as the blank group, and all the other mouse tail vein injection streptozotocin (in 4 ℃ of ice baths, with the preparation of 0.05M citric acid pH4.5 solution, using immediately) 200mg/kg causes diabetes model.Inject back 72 hours mice socket of the eye veins and get blood and survey blood glucose, deletion does not cause diabetes model person (fasting is 12 hours before surveying, and blood glucose value is lower than 11.11mmol/L); Continue to employ mice and be divided into 5 groups at random, 10 every group, in 7 days, be administered once every day by dosage shown in the table 3; After the last administration 2 hours;, the socket of the eye vein is got blood, surveys blood glucose with ortho-aminotoluene method (ultramicro method).Result of the test is seen table 3.
These article of table 3 compositions causes the influence of mice hyperglycemia to streptozotocin
Compare with model control group: * P < 0.05; * P < 0.01; * * P < 0.01
The result shows: the high, medium and low dose groups of these article compositions causes that to streptozotocin the mice hyperglycemia all has tangible reduction effect.
4, these article compositions is to the influence of alloxan diabetes mouse blood sugar and serum insulin levels
80 of male mices are got 10 at random as the blank group, all the other mouse tail vein injection alloxan 70mg/kg; Cause diabetes model, inject back 96 hours mice socket of the eye veins and get blood and survey blood glucose, deletion does not cause diabetes model person or blood glucose superelevation person (blood glucose value is lower than 20mmol/L and is higher than 40mmol/L and discards) with ortho-aminotoluene method (ultramicro method); Continue to employ mice and be divided into 5 groups immediately at random, 10 every group, weigh every day, amount of drinking water, appetite and urine just measures; In 12 days, be administered once every day by dosage shown in the table 4; After the last administration 2 hours, the socket of the eye vein was got blood, separation of serum; Survey blood glucose with glucose oxidase method, measure insulin content with radio immunoassay.Result of the test is seen table 4.
These article of table 4 are to the influence of alloxan diabetes mouse blood sugar and serum insulin levels
Compare with model control group: * P < 0.05; * P < 0.01
The result shows: under used dosage; These article cause that to alloxan the mice hyperglycemia has tangible reduction effect; And obvious dose-effect relationship is arranged, and can obviously improve symptoms more than three such as alloxan property hyperglycemia mice polydipsia, polyphagia, polyuria, but weight of mice is not had obvious influence; Its each dose groups also has facilitation to the release of insulin in the alloxan property hyperglycemia mice serum.
The present invention carries out detailed explanation through following embodiment, but does not mean that the present invention only limits to this, and specific embodiments is following:
Embodiment 1The preparation of extract
(1) Folium Mori extract preparation: Folium Mori extract 2 times with 14 times of distilled water, and each 2 hours, to filter, filtrating concentrates, and is drying to obtain Folium Mori extract;
(2) Herba Centellae extract preparation: Herba Centellae is extracted 3 times with 14 times of distilled water, and each 1 hour, to filter, filtrating concentrates, and is drying to obtain Herba Centellae extract;
(3) Fructus Arctii extract preparation: Fructus Arctii extracts 3 times with 8 times 70% alcoholic solution, and each 2 hours, filtration, filtrate recycling ethanol, concentrated, be drying to obtain Fructus Arctii extract;
(4) Semen Vitis viniferae extract preparation: Semen Vitis viniferae extracts 3 times with 8 times 50% alcoholic solution, and each 1 hour, filtration, filtrate recycling ethanol, concentrated, be drying to obtain Semen Vitis viniferae extract;
Embodiment 2(capsule)
Radix Panacis Quinquefolii fine powder 50g, Folium Mori extract 180g, Herba Centellae extract 70g, the 70g of Fructus Arctii extract, Semen Vitis viniferae extract 50g, right amount of auxiliary materials, mix homogeneously is granulated, drying, granulate incapsulates, and processes 1000, promptly gets.Each 2, every day 2 times.
Embodiment 3, (tablet)
Radix Panacis Quinquefolii fine powder 50g, Folium Mori extract 180g, Herba Centellae extract 70g, the 70g of Fructus Arctii extract, Semen Vitis viniferae extract 50g, right amount of auxiliary materials, mix homogeneously is granulated, drying, granulate, tabletting is processed 1000, promptly gets.Each 2, every day 2 times.
Claims (5)
1. the Chinese medicine composition with relevant diseases such as diabetes of preventing and treating and complication thereof is characterized in that: be made up of Radix Panacis Quinquefolii or extract, Folium Mori or extract, Herba Centellae or extract, Fructus Arctii or extract, Semen Vitis viniferae or extract.
2. the Chinese medicine composition with relevant diseases such as diabetes of preventing and treating and complication thereof according to claim 1 is characterized in that it is to be processed by the raw material of following weight parts:
Radix Panacis Quinquefolii 50-100 part, Folium Mori 200-500 part, Herba Centellae 100-300 part, Fructus Arctii 100-300 part, Semen Vitis viniferae 50-200 part.
3. the Chinese medicine composition with relevant diseases such as diabetes of preventing and treating and complication thereof according to claim 1 is characterized in that it is to be processed by the raw material of following weight parts:
Radix Panacis Quinquefolii extract 10-30 part, Folium Mori extract 40-100 part, Herba Centellae extract 20-50 part, the 20-50 of Fructus Arctii extract part, Semen Vitis viniferae extract 10-30 part.
4. Chinese medicine composition according to claim 1 is characterized in that: the method for preparing of said Chinese medicine composition may further comprise the steps:
(1) Folium Mori extract 1-3 time with 8-20 times of deionized water, and each 1-3 hour, to filter, filtrating concentrates, and drying is pulverized, and promptly gets Folium Mori extract; (2) Herba Centellae is extracted 2-4 time with 8-20 times of deionized water, and each 1-3 hour, to filter, filtrating concentrates, and drying is pulverized, and promptly gets Herba Centellae extract;
(3) Fructus Arctii extracts 2-3 time with the alcoholic solution of 8-14 times of 40%-90%, and each 1-3 hour, filter, filtrate recycling ethanol concentrates, and drying is pulverized, and promptly gets Fructus Arctii extract; (4) Semen Vitis viniferae extracts 2-3 time with the alcoholic solution of 8-14 times of 30%-80%, and each 1-3 hour, filter, filtrate recycling ethanol concentrates, and drying is pulverized, and promptly gets Semen Vitis viniferae extract;
(5) Radix Panacis Quinquefolii powder is broken into fine powder;
(6) 20 parts of the Folium Mori extract 40-100 part that makes, Herba Centellae extract 20-50 part, the 20-50 of Fructus Arctii extract part, Semen Vitis viniferae extract 10-30 part and Radix Panacis Quinquefolii powder are mixed by formula proportion after; Be mixed together with pharmaceutic adjuvant again, process oral formulations by conventional method.
5. the Chinese medicine composition with blood sugar reducing function as claimed in claim 1 is characterized in that: it is in hard capsule, soft capsule, tablet, granule, powder, pill, teabag, the medicated wine one or more.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210146660.1A CN102631482B (en) | 2012-05-12 | 2012-05-12 | Chinese medicinal composition for preventing and treating diabetes and complications |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210146660.1A CN102631482B (en) | 2012-05-12 | 2012-05-12 | Chinese medicinal composition for preventing and treating diabetes and complications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102631482A true CN102631482A (en) | 2012-08-15 |
| CN102631482B CN102631482B (en) | 2014-01-08 |
Family
ID=46616162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210146660.1A Active CN102631482B (en) | 2012-05-12 | 2012-05-12 | Chinese medicinal composition for preventing and treating diabetes and complications |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102631482B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208478A (en) * | 2014-09-12 | 2014-12-17 | 灌阳千家洞瑶之源生物科技有限公司 | Yao medicine composition for treating diabetes mellitus and preparation method thereof |
| CN108095118A (en) * | 2018-01-17 | 2018-06-01 | 长江师范学院 | A kind of slimming health food |
| CN112980772A (en) * | 2021-03-09 | 2021-06-18 | 广东医科大学 | Method for detecting autophagy effect of anthocyanin-induced mouse islet beta cells |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401365A (en) * | 2002-09-19 | 2003-03-12 | 太极集团有限公司 | Chinese health medicine |
| CN1586596A (en) * | 2004-07-26 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | American ginseng and its extract oral disintegration tablet and its preparing process |
| CN101757115A (en) * | 2008-10-10 | 2010-06-30 | 郇心清 | American ginseng mulberry leaf buccal tablet |
-
2012
- 2012-05-12 CN CN201210146660.1A patent/CN102631482B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1401365A (en) * | 2002-09-19 | 2003-03-12 | 太极集团有限公司 | Chinese health medicine |
| CN1586596A (en) * | 2004-07-26 | 2005-03-02 | 北京科信必成医药科技发展有限公司 | American ginseng and its extract oral disintegration tablet and its preparing process |
| CN101757115A (en) * | 2008-10-10 | 2010-06-30 | 郇心清 | American ginseng mulberry leaf buccal tablet |
Non-Patent Citations (4)
| Title |
|---|
| 刘湘红等: "葡萄籽原花青素对2型糖尿病大鼠血清中SOD GSH MDA及NO表达的影响", 《中国药物与临床》 * |
| 李向荣等: "桑叶提取液对实验性糖尿病大鼠血糖、LPO含量及SOD水平的影响", 《中国老年学杂志》 * |
| 王海颖等: "牛蒡子提取物对糖尿病大鼠肾脏蛋白激酶C活性作用的研究", 《中国中医基础医学杂志》 * |
| 郑承红等: "积雪草对2型糖尿病大鼠胰岛素抵抗影响的研究", 《内科急危重症杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104208478A (en) * | 2014-09-12 | 2014-12-17 | 灌阳千家洞瑶之源生物科技有限公司 | Yao medicine composition for treating diabetes mellitus and preparation method thereof |
| CN108095118A (en) * | 2018-01-17 | 2018-06-01 | 长江师范学院 | A kind of slimming health food |
| CN112980772A (en) * | 2021-03-09 | 2021-06-18 | 广东医科大学 | Method for detecting autophagy effect of anthocyanin-induced mouse islet beta cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102631482B (en) | 2014-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN102293273A (en) | Health tea capable of adjusting blood pressure, blood sugar and blood fat and preventing thrombus and apoplexy | |
| CN101543248B (en) | A cold tea especially suitable for 'three high and one acid' population and method for preparing same | |
| CN103446385A (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
| CN101085039B (en) | Composition for preventing and treating diabetes (hyperglycaemia) and its preparation method | |
| CN103349121B (en) | Hyperglycemia-hyperlipidemia-hypertension relieving health protection tea and preparation method thereof | |
| CN104173451A (en) | Application of natural pharmaceutical composition in blood glucose-reducing drugs and health food | |
| CN104474472B (en) | Buccal lozenge of lectuce tea and its production method with three high drop effect | |
| CN102631482B (en) | Chinese medicinal composition for preventing and treating diabetes and complications | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102579587B (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications thereof | |
| CN102488830A (en) | Pharmaceutical composition for lowering blood sugar | |
| CN103705578A (en) | Traditional Chinese medicine preparation with functions of reducing blood fat and inhibiting blood glucose increase and preparation method thereof | |
| CN101062283B (en) | Tea for reducing blood sugar and its preparing method | |
| CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
| CN110882362A (en) | Traditional Chinese medicine food therapy product for conditioning diabetes and preparation method thereof | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition | |
| CN102579589B (en) | Application of Chinese medicinal composition in preparing hypoglycemic drugs or health-promoting products | |
| CN104800600A (en) | Medicine for treating hypertension | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN103525640A (en) | Energy-keeping yang-tonifying wine | |
| CN102824446B (en) | Medicinal composition with anti-fatigue effect as well as preparation method and application thereof | |
| CN102366481B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN1463734A (en) | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same | |
| CN105663224A (en) | Composition for treating cardiovascular and cerebrovascular diseases and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Shanheng Inventor before: Nan Minlun Inventor before: He Yufang Inventor before: Wang Lianping Inventor before: Zhao Yuwei Inventor before: Ma Jisheng Inventor before: Zhao Quancheng |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170531 Address after: 264006 No. 14, Xiangjiang Road, Yantai Development Zone, Shandong 1, China Patentee after: YANTAI HUAXIN BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: 130012 Changchun high tech Zone, Jilin pioneering Street No. 155 Patentee before: Zhao Quancheng |
|
| CB03 | Change of inventor or designer information |
Inventor after: Han Chaowu Inventor after: Hou Jian Inventor before: Wang Shanheng |
|
| CB03 | Change of inventor or designer information |